TGFβ1 is the driver and primary mediator of changes in the tumor microenvironment and is a critical factor that limits the efficacy of checkpoint inhibitor therapy for patients with several types of solid tumors (9, 10). The gene discussed is TGFB1; the disease is neoplasm.